According to the National Medical Products Administration's Announcement No. 103 of 2024, the import, sale, and use of the UCB Pharma S.A. Levetiracetam Injection Concentrate have been resumed.
Based on the results of the overseas non-site inspection, the National Medical Products Administration (NMPA) issued Announcement No. 67 on August 22, 2022, deciding to suspend the import, sale, and use of UCB Pharma S.A.'s Levetiracetam Injection Concentrate ...
view
detail